STEGLATRO (Merck Sharp & Dohme (Australia) Pty Ltd)
Product name
STEGLATRO
Date registered
Evaluation commenced
Decision date
Approval time
235 working days (255)
Active ingredients
ertugliflozin
Registration type
NCE/NBE
Indication
STEGLATRO (tablets) is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus as:
- monotherapy when metformin is considered inappropriate due to intolerance; or,
- in combination with other anti-hyperglycaemic agents.